Atherosclerosis
Volume 199, Issue 2 , Pages 402-407 , August 2008

Prevalence and determinants of coronary artery disease in males and females with familial combined hyperlipidaemia

Received 20 August 2007 ,Revised 10 November 2007 ,Accepted 15 November 2007.

References 

  1. Voors-Pette C, de Bruin TW. Excess coronary heart disease in familial combined hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis. 2001;157:481–489
  2. Naukkarinen J, Ehnholma C, Peltonen L. Genetics of familial combined hyperlipidemia. Curr Opin Lipidol. 2006;17:285–290
  3. Veerkamp M, de Graaf J, Bredie S, et al. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol. 2002;22:274–282
  4. Shoulders CC, Johnes EL, Naoumona RP. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet. 2004;13:149–160
  5. de Graaf J, Veerkamp M, Stalenhoef A. Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids. J R Soc Med. 2002;95(Suppl. 42):46–53
  6. Skoumas I, Masoura C, Pitsavos C, et al. Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Int J Cardiol. 2007;121:178–183
  7. Eaton C. Traditional and emerging risk factors for cardiovascular disease. Prim Care. 2005;32:963–976
  8. Williams CM. Lipid metabolism in women. Proc Nutr Soc. 2004;63:153–160
  9. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2 003;26 (Suppl 1): S21-24.
  10. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001). Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
  11. Aguilar Salinas C, Zamora M, Gomez-Dıaz R, et al. Familial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesis. Semin Vasc Med. 2004;2:203–209
  12. Gaddi A, Galetti C, Pauciullo P, Arca M. Familial combined hyperlipoproteinemia: experts’ panel position on diagnostic criteria for clinical practice. Committee of experts of the Atherosclerosis and Dysmetabolic Disorders, Study Group. Nutr Metab Cardiovasc Dis. 1999;9:304–311
  13. Assmann G, Schulte H. Relation of HDL-cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Munster Study. Am J Cardiol. 1992;70:733–737
  14. de Graaf J, van der Vleuten G, Stalenhoef A. Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia. Semin Vasc Med. 2004;4:229–240
  15. Skoumas J, Papadimitriou L, Pitsavos C, et al. Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia. Metabolism. 2007;56:135–141
  16. Sniderman A, Bailey S, Engert J. Familial combined hyperlipidemia: how can genetic disorders be common, complex, and comprehensible?. Clin Sci (Lond). 2007;113:365–367
  17. Pitsavos C, Panagiotakos D, Chrysohoou C, Stefanadis C. Epidemiology of cardiovascular risk factors in Greece: aims, design and baseline characteristics of the ATTICA study. BMC Public Health. 2003;3:32–41
  18. Kaaja R, Poyhonen-Alho M. Insulin resistance and sympathetic overactivity in women. J Hypertens. 2006;24:131–141
  19. Williams R, Hunt S, Hopkins P, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259:333–344
  20. Le N, Brown W, Davis W, et al. Comparison of the relation of triglyceride-rich lipoproteins and muscular artery compliance in healthy women versus healthy men. Am J Cardiol. 2005;95:1049–1054
  21. Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ. 2007;176(Suppl.):1–44
  22. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151
  23. Kapoor D, Malkin C, Channer K, Jones T. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005;63:239–250
  24. Smith G, Ben-Shlomo Y, Beswick A, et al. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation. 2005;112:332–340
  25. Juo S, Bredie S, Kiemeney L, Demacker P, Stalenhoef A. A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. Am J Hum Genet. 1998;63:586–594
  26. Carr M, Brunzell J. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89:2601–2607
  27. Rigal M, Ruidavets J, Viguier A, et al. Lipoprotein(a) and risk of ischemic stroke in young adults. J Neurol Sci. 2007;252:39–44
  28. Marcucci R, Sofi F, Fedi S, et al. Thrombophilic risk factors in patients with severe carotid atherosclerosis. J Thromb Haemost. 2005;3:502–507
  29. Ohira T, Schreiner P, Morrisett J, et al. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2006;37:1407–1412
  30. Cantin B, Despres J, Lamarche B, et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol. 2002;89:662–666
  31. Gregg E, Gu Q, Cheng Y, Narayan K, Cowie C. Mortality trends in men and women with diabetes, 1971–2000. Ann Intern Med. 2007;147:149–155
  32. Natarajan S, Liao Y, Cao G, Lipsitz S, McGee D. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med. 2003;163:1735–1740
  33. Bass K, Newschaffer C, Klag M, Bush T. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153:2209–2216

PII: S0021-9150(07)00742-3

doi: 10.1016/j.atherosclerosis.2007.11.021

Atherosclerosis
Volume 199, Issue 2 , Pages 402-407 , August 2008

Article Tools